Drug intelligence / Profile preview

N7.1 peptide

Development stage: Preclinical
Modality: Peptides

Overview

N7.1 peptide is a shortened fragment of the 16-amino acid N7 peptide, which itself is derived from the Hsp70 protein. This 8-amino acid peptide (SDNQPGVL) functions by inhibiting the interaction of TREM-1 with its ligands. Preclinical studies have demonstrated that N7.1 peptide exhibits protective effects in the development of sepsis in mice, suggesting its potential utility in anti-inflammatory and antitumor therapies.

Targets

TREM1 (Triggering receptor expressed on myeloid cells 1)

Beyond the preview

Go deeper on N7.1 peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N7.1 peptide.

Explore the full profile